Amarin Corp PLC (AMRN): Total Assets
$670.77M
As of 2025-12-31
$624.36M
As of 2026-06-30
-8.9%
3-year compound annual growth
-7.0%
5-year compound annual growth
+14.5%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $670.77M | -2.1% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $685.35M | -17.6% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $831.68M | -6.1% | 2025-03-12, Balance as of period end |
| 2022-12-31 | $886.18M | -17.0% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $1.07B | +10.6% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $966.02M | +9.5% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $882.21M | +128.7% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $385.71M | +138.7% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $161.60M | -3.2% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $167.00M | -3.6% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $173.23M | +1.2% | 2017-03-01, Balance as of period end |
| 2014-12-31 | $171.11M | -32.2% | 2016-02-25, Balance as of period end |
| 2013-12-31 | $252.48M | -18.8% | 2015-03-03, Balance as of period end |
| 2012-12-31 | $310.86M | +146.0% | 2014-02-27, Balance as of period end |
| 2011-12-31 | $126.38M | +257.3% | 2013-02-28, Balance as of period end |
| 2010-12-31 | $35.37M | n/a | 2012-02-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Amarin Corp PLC (AMRN) | 2025-12-31 | $670.77M | -2.1% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $488.95M | -25.5% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $1.11B | -1.3% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $216.30M | +1.4% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $364.39M | -24.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $376.56M | +70.6% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $480.20M | +22.4% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $338.02M | -45.1% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $770.58M | -23.6% |
Compare AMRN, VNDA, IDYA, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗